Premium
Ixekizumab: targeting plaque psoriasis and psoriatic arthritis
Author(s) -
Chaplin Steve
Publication year - 2019
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1743
Subject(s) - ixekizumab , medicine , psoriatic arthritis , psoriasis , plaque psoriasis , dermatology , secukinumab , monoclonal antibody , arthritis , immunology , antibody
Ixekizumab (Taltz) is an anti‐interleukin‐17A monoclonal antibody therapy for the treatment of adults with plaque psoriasis or psoriatic arthritis. This article discusses its efficacy and place in therapy.